Search clinical trials for: Faster-acting insulin aspart

Total 4058 results

Novo Nordisk A/S

Completed

A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes (onset® 4)

Diabetes | Diabetes Mellitus, Type 1

United States, Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes (onset®7)

Diabetes | Diabetes Mellitus, Type 1

Germany, United States, India, Israel, Italy, Russian Federation, Japan, Finland, Serbia, Turkey, Bulgaria, Estonia, Czechia, Lithuania, Ukraine, Poland, Latvia, Puerto Rico
Novo Nordisk A/S

Completed

A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes (Onset® 5)

Diabetes | Diabetes Mellitus, Type 1

United States, Russian Federation, United Kingdom, Canada, France, Netherlands, Belgium, Germany, Slovenia
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes (onset® 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Israel, Russian Federation, Slovakia, Canada, Serbia, United Kingdom, Puerto Rico
Novo Nordisk A/S

Completed

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes (onset®8)

Diabetes | Diabetes Mellitus, Type 1

United States, India, Israel, Italy, Japan, Russian Federation, Canada, Austria, Taiwan, Serbia, Germany, Bulgaria, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Diabetes Mellitus, Type 1

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes (onset® 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Finland, Belgium, Hungary, United Kingdom, Germany, Canada, Czechia
Novo Nordisk A/S

Completed

Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

China
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (onset 9)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Croatia, Italy, Russian Federation, Spain, Canada, Serbia, Slovakia, Germany, Greece, Korea, Republic of, Czechia, Puerto Rico, Bulgaria, Romania, Argentina, Ukraine
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Austria
Novo Nordisk A/S

Completed

An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

India
Novo Nordisk A/S

Completed

A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes (BOOST)

Diabetes Mellitus, Type 2 | Diabetes

China
University of Cambridge
Cambridge University Hospitals NHS Foundation Trust; Nottingham University... and other collaborators

Completed

FASter Insulin in Closed-loop Technology in Children (FAST-Kids)

Type 1 Diabetes Mellitus

United Kingdom
Novo Nordisk A/S

Completed

Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Mountain Diabetes and Endocrine Center

Unknown

The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus (PLATEAU)

Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Egypt
University of Ljubljana, Faculty of Medicine

Completed

Closed-Loop With Faster Aspart in Young Adults With Type 1 Diabetes

Type 1 Diabetes Mellitus

Slovenia
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (onset® 3)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Mexico, Argentina, Slovenia, Romania
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Denmark
Novo Nordisk A/S

Completed

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland
Novo Nordisk A/S

Completed

Investigation of the Response Relationship of NN5401 in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Japan, Malaysia, Taiwan, Korea, Republic of, Hong Kong
Novo Nordisk A/S

Completed

Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

India, Denmark, Sweden, Malaysia, Poland, Turkey, Finland, Australia, Thailand, Taiwan
Novo Nordisk A/S

Completed

A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Effect of NN5401 in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin (Mix2Mix)

Diabetes Mellitus, Type 2 | Diabetes

Belgium, Luxembourg
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

Diabetes Mellitus, Type 2 | Diabetes

United Arab Emirates, Malaysia, India, South Africa, Algeria, Lebanon
Novo Nordisk A/S

Completed

Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Russian Federation, Ukraine

3

Subscribe